313 related articles for article (PubMed ID: 23942918)
21. The impact of the 21-gene Recurrence Score assay on clinical decision-making in node-positive (up to 3 positive nodes) estrogen receptor-positive breast cancer patients.
Stemmer SM; Klang SH; Ben-Baruch N; Geffen DB; Steiner M; Soussan-Gutman L; Merling S; Svedman C; Rizel S; Lieberman N
Breast Cancer Res Treat; 2013 Jul; 140(1):83-92. PubMed ID: 23801158
[TBL] [Abstract][Full Text] [Related]
22. Development of a Nomogram to Predict the Recurrence Score of 21-Gene Prediction Assay in Hormone Receptor-Positive Early Breast Cancer.
Yoo SH; Kim TY; Kim M; Lee KH; Lee E; Lee HB; Moon HG; Han W; Noh DY; Han SW; Kim TY; Im SA
Clin Breast Cancer; 2020 Apr; 20(2):98-107.e1. PubMed ID: 31522959
[TBL] [Abstract][Full Text] [Related]
23. Relationship of pathological features and a 21 gene expression assay in younger versus older women with node-negative endocrine receptor-positive breast cancer.
Mutonga M; Speedy S; Rademaker A; Liu D; Uthe R; Jain S; Gradishar WJ; Flaum L; Santa-Maria CA
Breast Cancer Res Treat; 2019 Jul; 176(1):95-100. PubMed ID: 30977026
[TBL] [Abstract][Full Text] [Related]
24. Correlating Ki67 and other prognostic markers with Oncotype DX recurrence score in early estrogen receptor-positive breast cancer.
Tan AC; Li BT; Nahar K; Danieletto S; Fong ES; Currer T; Parasyn A; Middleton P; Wong H; Smart D; Rutovitz JJ; McCloud P; Hughes TM; Marx GM
Asia Pac J Clin Oncol; 2018 Apr; 14(2):e161-e166. PubMed ID: 28960862
[TBL] [Abstract][Full Text] [Related]
25. First Prospective Multicenter Italian Study on the Impact of the 21-Gene Recurrence Score in Adjuvant Clinical Decisions for Patients with ER Positive/HER2 Negative Breast Cancer.
Dieci MV; Guarneri V; Giarratano T; Mion M; Tortora G; De Rossi C; Gori S; Oliani C; Merlini L; Pasini F; Bonciarelli G; Griguolo G; Orvieto E; Michieletto S; Saibene T; Del Bianco P; De Salvo GL; Conte P
Oncologist; 2018 Mar; 23(3):297-305. PubMed ID: 29133514
[TBL] [Abstract][Full Text] [Related]
26. Factors influencing Oncotype DX use in the management of early breast cancer: a single centre experience.
Zhu X; Dent S; Paquet L; Zhang T; Graham N; Song X
Eur J Cancer; 2014 Oct; 50(15):2544-9. PubMed ID: 25129366
[TBL] [Abstract][Full Text] [Related]
27. The effect of Oncotype DX recurrence score on treatment recommendations for patients with estrogen receptor-positive early stage breast cancer and correlation with estimation of recurrence risk by breast cancer specialists.
Joh JE; Esposito NN; Kiluk JV; Laronga C; Lee MC; Loftus L; Soliman H; Boughey JC; Reynolds C; Lawton TJ; Acs PI; Gordan L; Acs G
Oncologist; 2011; 16(11):1520-6. PubMed ID: 22016474
[TBL] [Abstract][Full Text] [Related]
28. The Level of Agreement Among Medical Oncologists on Adjuvant Chemotherapy Decision for Breast Cancer in Pre and Post-Oncotype DX Settings.
Alkushi A; Omair A; Masuadi E; Alamri G; Abusanad A; Abdelhafiez N; Mohamed AE; Abulkhair O
Cureus; 2021 Feb; 13(2):e13298. PubMed ID: 33738150
[TBL] [Abstract][Full Text] [Related]
29. Correlation between postoperative treatment selection and prognosis determined using the Oncotype DX® test data: a retrospective multicenter study in Japan.
Tsuchida Y; Niikura N; Chishima T; Mizuno M; Kawate T; Fuchikami H; Miyoshi Y; Sakai T; Kotani H; Kondo N; Hayashi N
Breast Cancer; 2024 May; 31(3):401-408. PubMed ID: 38451415
[TBL] [Abstract][Full Text] [Related]
30. Oncotype DX in Bilateral Synchronous Primary Invasive Breast Cancer.
Karsten M; Stempel M; Radosa J; Patil S; King TA
Ann Surg Oncol; 2016 Feb; 23(2):471-6. PubMed ID: 26340863
[TBL] [Abstract][Full Text] [Related]
31. Utility of Oncotype DX Risk Assessment in Patients With Invasive Lobular Carcinoma.
Tsai ML; Lillemoe TJ; Finkelstein MJ; Money JE; Susnik B; Grimm E; Kang SH; Swenson KK
Clin Breast Cancer; 2016 Feb; 16(1):45-50. PubMed ID: 26385397
[TBL] [Abstract][Full Text] [Related]
32. Correlation of the Ki67 Working Group prognostic risk categories with the Oncotype DX Recurrence Score in early breast cancer.
Patel R; Hovstadius M; Kier MW; Moshier EL; Zimmerman BS; Cascetta K; Jaffer S; Sparano JA; Tiersten A
Cancer; 2022 Oct; 128(20):3602-3609. PubMed ID: 35947048
[TBL] [Abstract][Full Text] [Related]
33. Evaluation of Oncotype DX Recurrence Score as a prognostic factor in Japanese women with estrogen receptor-positive, node-negative primary Stage I or IIA breast cancer.
Yorozuya K; Takeuchi T; Yoshida M; Mouri Y; Kousaka J; Fujii K; Nakano S; Fukutomi T; Hara K; Ichihara S; Lin Y; Kikuchi S
J Cancer Res Clin Oncol; 2010 Jun; 136(6):939-44. PubMed ID: 19946706
[TBL] [Abstract][Full Text] [Related]
34. The American Joint Commission Cancer 8th Edition Prognostic Stage Including Oncotype DX® Recurrence Score: Impact on Staging of Early Breast Cancer.
O'Cearbhaill R; Gannon JM; Prichard RS; Walshe JM; McDermott E; Quinn CM
Pathobiology; 2019; 86(2-3):77-82. PubMed ID: 30347405
[TBL] [Abstract][Full Text] [Related]
35. Gene expression profiling for guiding adjuvant chemotherapy decisions in women with early breast cancer: an evidence-based and economic analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2010; 10(23):1-57. PubMed ID: 23074401
[TBL] [Abstract][Full Text] [Related]
36. Association between Oncotype DX recurrence score and dynamic contrast-enhanced MRI features in patients with estrogen receptor-positive HER2-negative invasive breast cancer.
Kim HJ; Choi WJ; Kim HH; Cha JH; Shin HJ; Chae EY
Clin Imaging; 2021 Jul; 75():131-137. PubMed ID: 33548871
[TBL] [Abstract][Full Text] [Related]
37. A cost-consequence model of using the 21-gene assay to identify patients with early-stage node-positive breast cancer who benefit from adjuvant chemotherapy in the Netherlands.
Simons MJHG; Machielsen PM; Spoorendonk JA; Ignacio T; Drost PB; Jacobs T; de Jongh FE
J Med Econ; 2024; 27(1):445-454. PubMed ID: 38436289
[TBL] [Abstract][Full Text] [Related]
38. Impact of Oncotype DX breast Recurrence Score testing on adjuvant chemotherapy use in early breast cancer: Real world experience in Greater Manchester, UK.
Loncaster J; Armstrong A; Howell S; Wilson G; Welch R; Chittalia A; Valentine WJ; Bundred NJ
Eur J Surg Oncol; 2017 May; 43(5):931-937. PubMed ID: 28111076
[TBL] [Abstract][Full Text] [Related]
39. 21-gene recurrence score and adjuvant chemotherapy decisions in patients with invasive lobular breast cancer.
Chen XH; Zhang WW; Wang J; Sun JY; Li FY; He ZY; Wu SG
Biomark Med; 2019 Feb; 13(2):83-93. PubMed ID: 30565472
[TBL] [Abstract][Full Text] [Related]
40. Community clinical practice patterns and mortality in patients with intermediate oncotype DX recurrence scores: Who benefits from chemotherapy?
Ibraheem AF; Press DJ; Olopade OI; Huo D
Cancer; 2019 Jan; 125(2):213-222. PubMed ID: 30387876
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]